Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPC-201 · 2 trials · 2 indications
To evaluate the safety labs and adverse events from baseline, during the study and at the end of the study.
Number of participants who reached Donepezil Maximum Tolerated Dose of 40 mg/day (highest allowed per protocol) at the end of donepezil dose titration phase and at the end of the maintenance phase.
| Arm | Type | Description |
|---|---|---|
| CPC-201 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CPC-201 | DRUG | - |
Inclusion Criteria: 1. Have signed an Institutional Review Board (IRB) approved informed consent document indicating that they understand the purpose of and procedures required by the study and are willing to participate in the study and comply with all study procedures and restrictions. Informed c...
Top 20 of 30 competitors
CPC-201 is an investigational small molecule being studied for Alzheimer's disease and dementia of the Alzheimer's type. It has been evaluated in Phase 2 clinical trials in patients aged 50 years and older. It is not approved for any indication and remains in clinical development.
CPC-201 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor behind the clinical program evaluating CPC-201 in Alzheimer's disease and dementia of the Alzheimer's type.
CPC-201 is in Phase 2 development. Two Phase 2 trials have been conducted, both of which are now completed. The program has not advanced beyond Phase 2, and CPC-201 is investigational rather than approved.
CPC-201 has been studied in two completed Phase 2 trials: NCT02185053, a Phase II study of CPC-201 in Alzheimer's disease type dementia, and NCT02434666, a long term extension safety study in patients with dementia of the Alzheimer's type who completed study CPC-001-07. Both were conducted in the United States.
The CPC-201 Phase 2 program enrolled 41 patients in NCT02185053 and 21 patients in the extension study NCT02434666. Both trials were uncontrolled, were not randomized, and were not double blinded, and they enrolled patients aged 50 years and older.